Bristol Metaglip (correction)
Executive Summary
Bristol-Myers Squibb's Metaglip (glipizide/metformin) clears FDA Oct. 21. "The Pink Sheet" (1Oct. 28, p. 13) incorrectly reported the approval date...
You may also be interested in...
Bristol Metaglip Launch Set For November; Third Metformin Line-Extension
Bristol-Myers Squibb's antidiabetic Metaglip (glipizide/metformin) is expected to launch in November following its Oct. 21 approval
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.